ArticleMedicine2026
Association between the metabolic score for visceral fat and mortality outcomes in stroke patients: A national cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke survivors face an elevated risk of subsequent mortality. While visceral adiposity is linked to adverse cardiometabolic outcomes, traditional anthropometric indices fail to adequately capture its metabolic burden. The metabolic score for visceral fat (METS-VF) is a novel indicator of visceral fat-related metabolic activity; however, its prognostic value in stroke patients remains unclear. This national cohort study included 1557 adults with a history of stroke from the National Health and Nutrition Examination Survey 1999 to 2018. METS-VF was calculated and stratified into tertiles. All-cause and cardiovascular mortality data were obtained via linkage to the National Death Index. Associations between METS-VF and mortality outcomes were evaluated using Kaplan-Meier survival analysis, multivariable Cox proportional hazards models, and restricted cubic splines (RCS). During a median follow-up of 80 months, 665 all-cause deaths and 262 cardiovascular deaths occurred. In fully adjusted models, METS-VF served as an independent predictor for both all-cause (hazard ratio [HR], 1.62; 95% CI, 1.05-2.50) and cardiovascular mortality (HR, 1.81; 95% CI, 1.09-3.67). Participants in the highest METS-VF tertile exhibited the greatest mortality risk. Furthermore, RCS analyses confirmed significant linear dose-response relationships with no evidence of nonlinearity. These associations remained robust across various demographic and clinical subgroups. Higher METS-VF is independently and linearly associated with increased subsequent all-cause and cardiovascular mortality among individuals with a history of stroke. As a highly accessible metabolic indicator, METS-VF can enhance risk stratification and guide targeted secondary prevention strategies in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.